nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2C8—Tazarotene—psoriasis	0.0849	0.131	CbGbCtD
Loperamide—CYP2B6—Cholecalciferol—psoriasis	0.0478	0.0738	CbGbCtD
Loperamide—CYP2D6—Hydroxyurea—psoriasis	0.0381	0.0589	CbGbCtD
Loperamide—CYP2C8—Cholecalciferol—psoriasis	0.0362	0.0559	CbGbCtD
Loperamide—CYP2C8—Mycophenolate mofetil—psoriasis	0.0314	0.0485	CbGbCtD
Loperamide—CYP3A4—Calcitriol—psoriasis	0.0285	0.044	CbGbCtD
Loperamide—CYP2C8—Hydrocortisone—psoriasis	0.0252	0.0389	CbGbCtD
Loperamide—CYP2C8—Cyclosporine—psoriasis	0.0238	0.0367	CbGbCtD
Loperamide—CYP2D6—Cholecalciferol—psoriasis	0.0231	0.0357	CbGbCtD
Loperamide—CYP3A4—Methoxsalen—psoriasis	0.0222	0.0342	CbGbCtD
Loperamide—ABCB1—Mycophenolate mofetil—psoriasis	0.0213	0.0328	CbGbCtD
Loperamide—POMC—vertebral column—psoriasis	0.0208	0.432	CbGeAlD
Loperamide—CYP2B6—Dexamethasone—psoriasis	0.0207	0.0319	CbGbCtD
Loperamide—ABCB1—Betamethasone—psoriasis	0.0182	0.0282	CbGbCtD
Loperamide—ABCB1—Prednisolone—psoriasis	0.018	0.0278	CbGbCtD
Loperamide—ABCB1—Hydrocortisone—psoriasis	0.0171	0.0263	CbGbCtD
Loperamide—ABCB1—Prednisone—psoriasis	0.017	0.0262	CbGbCtD
Loperamide—ABCB1—Cyclosporine—psoriasis	0.0161	0.0249	CbGbCtD
Loperamide—CYP2C8—Dexamethasone—psoriasis	0.0157	0.0242	CbGbCtD
Loperamide—CYP2D6—Cyclosporine—psoriasis	0.0152	0.0234	CbGbCtD
Loperamide—CYP3A4—Cholecalciferol—psoriasis	0.0147	0.0227	CbGbCtD
Loperamide—POMC—skin epidermis—psoriasis	0.0128	0.265	CbGeAlD
Loperamide—CYP3A4—Mycophenolate mofetil—psoriasis	0.0127	0.0197	CbGbCtD
Loperamide—CYP3A4—Triamcinolone—psoriasis	0.0127	0.0197	CbGbCtD
Loperamide—CYP3A4—Betamethasone—psoriasis	0.0109	0.0169	CbGbCtD
Loperamide—CYP3A4—Prednisolone—psoriasis	0.0108	0.0166	CbGbCtD
Loperamide—ABCB1—Dexamethasone—psoriasis	0.0106	0.0164	CbGbCtD
Loperamide—CYP3A4—Hydrocortisone—psoriasis	0.0102	0.0158	CbGbCtD
Loperamide—CYP3A4—Prednisone—psoriasis	0.0102	0.0157	CbGbCtD
Loperamide—CYP2D6—Dexamethasone—psoriasis	0.01	0.0154	CbGbCtD
Loperamide—CYP3A4—Cyclosporine—psoriasis	0.00965	0.0149	CbGbCtD
Loperamide—ABCB1—Methotrexate—psoriasis	0.00853	0.0132	CbGbCtD
Loperamide—CYP3A4—Dexamethasone—psoriasis	0.00636	0.00981	CbGbCtD
Loperamide—POMC—skin of body—psoriasis	0.00395	0.082	CbGeAlD
Loperamide—CALM2—endothelium—psoriasis	0.00253	0.0524	CbGeAlD
Loperamide—CALM1—endothelium—psoriasis	0.00252	0.0522	CbGeAlD
Loperamide—CALM2—skin of body—psoriasis	0.00108	0.0224	CbGeAlD
Loperamide—CALM1—skin of body—psoriasis	0.00107	0.0223	CbGeAlD
Loperamide—CALM3—tendon—psoriasis	0.00105	0.0217	CbGeAlD
Loperamide—CALM2—tendon—psoriasis	0.000822	0.017	CbGeAlD
Loperamide—CALM1—tendon—psoriasis	0.000818	0.017	CbGeAlD
Loperamide—CYP2B6—skin of body—psoriasis	0.000803	0.0166	CbGeAlD
Loperamide—Headache—Calcitriol—psoriasis	0.000424	0.00244	CcSEcCtD
Loperamide—Somnolence—Hydroxyurea—psoriasis	0.00042	0.00242	CcSEcCtD
Loperamide—Dyspepsia—Hydroxyurea—psoriasis	0.000416	0.0024	CcSEcCtD
Loperamide—Diarrhoea—Acitretin—psoriasis	0.000412	0.00237	CcSEcCtD
Loperamide—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00041	0.00237	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.00041	0.00236	CcSEcCtD
Loperamide—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000408	0.00235	CcSEcCtD
Loperamide—Discomfort—Mycophenolic acid—psoriasis	0.000408	0.00235	CcSEcCtD
Loperamide—Fatigue—Hydroxyurea—psoriasis	0.000407	0.00235	CcSEcCtD
Loperamide—Constipation—Hydroxyurea—psoriasis	0.000404	0.00233	CcSEcCtD
Loperamide—Dry mouth—Mycophenolic acid—psoriasis	0.000404	0.00233	CcSEcCtD
Loperamide—Nausea—Calcitriol—psoriasis	0.000402	0.00232	CcSEcCtD
Loperamide—Dizziness—Acitretin—psoriasis	0.000398	0.00229	CcSEcCtD
Loperamide—Dizziness—Fluocinolone Acetonide—psoriasis	0.000397	0.00229	CcSEcCtD
Loperamide—Nervous system disorder—Mycophenolic acid—psoriasis	0.000388	0.00224	CcSEcCtD
Loperamide—Flatulence—Cyclosporine—psoriasis	0.000386	0.00223	CcSEcCtD
Loperamide—Skin disorder—Mycophenolic acid—psoriasis	0.000384	0.00222	CcSEcCtD
Loperamide—Vomiting—Acitretin—psoriasis	0.000383	0.00221	CcSEcCtD
Loperamide—Vomiting—Fluocinolone Acetonide—psoriasis	0.000381	0.0022	CcSEcCtD
Loperamide—Rash—Acitretin—psoriasis	0.000379	0.00219	CcSEcCtD
Loperamide—Dermatitis—Acitretin—psoriasis	0.000379	0.00218	CcSEcCtD
Loperamide—Rash—Fluocinolone Acetonide—psoriasis	0.000378	0.00218	CcSEcCtD
Loperamide—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000378	0.00218	CcSEcCtD
Loperamide—Flatulence—Mycophenolate mofetil—psoriasis	0.000377	0.00217	CcSEcCtD
Loperamide—Headache—Acitretin—psoriasis	0.000377	0.00217	CcSEcCtD
Loperamide—Headache—Fluocinolone Acetonide—psoriasis	0.000376	0.00217	CcSEcCtD
Loperamide—Abdominal distension—Prednisone—psoriasis	0.000375	0.00216	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methotrexate—psoriasis	0.000372	0.00214	CcSEcCtD
Loperamide—Immune system disorder—Hydrocortisone—psoriasis	0.000362	0.00208	CcSEcCtD
Loperamide—Angioedema—Cyclosporine—psoriasis	0.000358	0.00207	CcSEcCtD
Loperamide—Nausea—Acitretin—psoriasis	0.000357	0.00206	CcSEcCtD
Loperamide—Nausea—Fluocinolone Acetonide—psoriasis	0.000356	0.00205	CcSEcCtD
Loperamide—Somnolence—Mycophenolic acid—psoriasis	0.000352	0.00203	CcSEcCtD
Loperamide—Angioedema—Mycophenolate mofetil—psoriasis	0.00035	0.00202	CcSEcCtD
Loperamide—Dyspepsia—Mycophenolic acid—psoriasis	0.000348	0.00201	CcSEcCtD
Loperamide—Hypersensitivity—Hydroxyurea—psoriasis	0.000348	0.00201	CcSEcCtD
Loperamide—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000342	0.00197	CcSEcCtD
Loperamide—Fatigue—Mycophenolic acid—psoriasis	0.000341	0.00197	CcSEcCtD
Loperamide—Asthenia—Hydroxyurea—psoriasis	0.000339	0.00195	CcSEcCtD
Loperamide—Constipation—Mycophenolic acid—psoriasis	0.000338	0.00195	CcSEcCtD
Loperamide—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.000336	0.00194	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000332	0.00191	CcSEcCtD
Loperamide—Discomfort—Cyclosporine—psoriasis	0.00033	0.0019	CcSEcCtD
Loperamide—Dry mouth—Cyclosporine—psoriasis	0.000327	0.00188	CcSEcCtD
Loperamide—Angioedema—Prednisolone—psoriasis	0.000326	0.00188	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000324	0.00187	CcSEcCtD
Loperamide—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000323	0.00186	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000323	0.00186	CcSEcCtD
Loperamide—Diarrhoea—Hydroxyurea—psoriasis	0.000323	0.00186	CcSEcCtD
Loperamide—Discomfort—Mycophenolate mofetil—psoriasis	0.000322	0.00186	CcSEcCtD
Loperamide—Anaphylactic shock—Cyclosporine—psoriasis	0.00032	0.00185	CcSEcCtD
Loperamide—Dry mouth—Mycophenolate mofetil—psoriasis	0.000319	0.00184	CcSEcCtD
Loperamide—Angioedema—Hydrocortisone—psoriasis	0.000318	0.00184	CcSEcCtD
Loperamide—Nervous system disorder—Cyclosporine—psoriasis	0.000314	0.00181	CcSEcCtD
Loperamide—Loss of consciousness—Prednisolone—psoriasis	0.000314	0.00181	CcSEcCtD
Loperamide—Abdominal pain—Mycophenolic acid—psoriasis	0.000313	0.0018	CcSEcCtD
Loperamide—Dizziness—Hydroxyurea—psoriasis	0.000312	0.0018	CcSEcCtD
Loperamide—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000312	0.0018	CcSEcCtD
Loperamide—Skin disorder—Cyclosporine—psoriasis	0.000311	0.00179	CcSEcCtD
Loperamide—Loss of consciousness—Hydrocortisone—psoriasis	0.000306	0.00177	CcSEcCtD
Loperamide—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000306	0.00177	CcSEcCtD
Loperamide—Skin disorder—Mycophenolate mofetil—psoriasis	0.000303	0.00175	CcSEcCtD
Loperamide—Vomiting—Hydroxyurea—psoriasis	0.0003	0.00173	CcSEcCtD
Loperamide—Discomfort—Prednisolone—psoriasis	0.0003	0.00173	CcSEcCtD
Loperamide—Angioedema—Triamcinolone—psoriasis	0.0003	0.00173	CcSEcCtD
Loperamide—Rash—Hydroxyurea—psoriasis	0.000298	0.00172	CcSEcCtD
Loperamide—Dermatitis—Hydroxyurea—psoriasis	0.000298	0.00172	CcSEcCtD
Loperamide—Headache—Hydroxyurea—psoriasis	0.000296	0.00171	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000295	0.0017	CcSEcCtD
Loperamide—Discomfort—Hydrocortisone—psoriasis	0.000293	0.00169	CcSEcCtD
Loperamide—Anaphylactic shock—Prednisolone—psoriasis	0.000291	0.00168	CcSEcCtD
Loperamide—Loss of consciousness—Triamcinolone—psoriasis	0.000288	0.00166	CcSEcCtD
Loperamide—Somnolence—Cyclosporine—psoriasis	0.000285	0.00164	CcSEcCtD
Loperamide—Anaphylactic shock—Hydrocortisone—psoriasis	0.000284	0.00164	CcSEcCtD
Loperamide—Asthenia—Mycophenolic acid—psoriasis	0.000284	0.00164	CcSEcCtD
Loperamide—Dyspepsia—Cyclosporine—psoriasis	0.000282	0.00162	CcSEcCtD
Loperamide—Nausea—Hydroxyurea—psoriasis	0.000281	0.00162	CcSEcCtD
Loperamide—Pruritus—Mycophenolic acid—psoriasis	0.00028	0.00161	CcSEcCtD
Loperamide—Nervous system disorder—Hydrocortisone—psoriasis	0.000279	0.00161	CcSEcCtD
Loperamide—Somnolence—Mycophenolate mofetil—psoriasis	0.000278	0.0016	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—psoriasis	0.000277	0.0016	CcSEcCtD
Loperamide—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000276	0.00159	CcSEcCtD
Loperamide—Skin disorder—Hydrocortisone—psoriasis	0.000276	0.00159	CcSEcCtD
Loperamide—Discomfort—Triamcinolone—psoriasis	0.000276	0.00159	CcSEcCtD
Loperamide—Fatigue—Cyclosporine—psoriasis	0.000276	0.00159	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000275	0.00158	CcSEcCtD
Loperamide—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000275	0.00158	CcSEcCtD
Loperamide—Constipation—Cyclosporine—psoriasis	0.000274	0.00158	CcSEcCtD
Loperamide—Dry mouth—Triamcinolone—psoriasis	0.000273	0.00158	CcSEcCtD
Loperamide—Angioedema—Dexamethasone—psoriasis	0.000272	0.00157	CcSEcCtD
Loperamide—Angioedema—Betamethasone—psoriasis	0.000272	0.00157	CcSEcCtD
Loperamide—Diarrhoea—Mycophenolic acid—psoriasis	0.000271	0.00156	CcSEcCtD
Loperamide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00027	0.00155	CcSEcCtD
Loperamide—Immune system disorder—Prednisone—psoriasis	0.000269	0.00155	CcSEcCtD
Loperamide—Anaphylactic shock—Triamcinolone—psoriasis	0.000268	0.00154	CcSEcCtD
Loperamide—Constipation—Mycophenolate mofetil—psoriasis	0.000267	0.00154	CcSEcCtD
Loperamide—Gastrointestinal pain—Cyclosporine—psoriasis	0.000262	0.00151	CcSEcCtD
Loperamide—Loss of consciousness—Dexamethasone—psoriasis	0.000262	0.00151	CcSEcCtD
Loperamide—Loss of consciousness—Betamethasone—psoriasis	0.000262	0.00151	CcSEcCtD
Loperamide—Dizziness—Mycophenolic acid—psoriasis	0.000262	0.00151	CcSEcCtD
Loperamide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000255	0.00147	CcSEcCtD
Loperamide—Urticaria—Cyclosporine—psoriasis	0.000254	0.00147	CcSEcCtD
Loperamide—Abdominal pain—Cyclosporine—psoriasis	0.000253	0.00146	CcSEcCtD
Loperamide—Vomiting—Mycophenolic acid—psoriasis	0.000252	0.00145	CcSEcCtD
Loperamide—Discomfort—Dexamethasone—psoriasis	0.00025	0.00144	CcSEcCtD
Loperamide—Discomfort—Betamethasone—psoriasis	0.00025	0.00144	CcSEcCtD
Loperamide—Dyspepsia—Hydrocortisone—psoriasis	0.00025	0.00144	CcSEcCtD
Loperamide—Rash—Mycophenolic acid—psoriasis	0.000249	0.00144	CcSEcCtD
Loperamide—Dermatitis—Mycophenolic acid—psoriasis	0.000249	0.00144	CcSEcCtD
Loperamide—Urticaria—Mycophenolate mofetil—psoriasis	0.000248	0.00143	CcSEcCtD
Loperamide—Headache—Mycophenolic acid—psoriasis	0.000248	0.00143	CcSEcCtD
Loperamide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000247	0.00142	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—psoriasis	0.000246	0.00142	CcSEcCtD
Loperamide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000246	0.00142	CcSEcCtD
Loperamide—Fatigue—Hydrocortisone—psoriasis	0.000245	0.00141	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—psoriasis	0.000244	0.00141	CcSEcCtD
Loperamide—Anaphylactic shock—Dexamethasone—psoriasis	0.000243	0.0014	CcSEcCtD
Loperamide—Anaphylactic shock—Betamethasone—psoriasis	0.000243	0.0014	CcSEcCtD
Loperamide—Nervous system disorder—Dexamethasone—psoriasis	0.000238	0.00137	CcSEcCtD
Loperamide—Nervous system disorder—Betamethasone—psoriasis	0.000238	0.00137	CcSEcCtD
Loperamide—Angioedema—Prednisone—psoriasis	0.000237	0.00137	CcSEcCtD
Loperamide—Hypersensitivity—Cyclosporine—psoriasis	0.000236	0.00136	CcSEcCtD
Loperamide—Dyspepsia—Triamcinolone—psoriasis	0.000236	0.00136	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—psoriasis	0.000235	0.00136	CcSEcCtD
Loperamide—Nausea—Mycophenolic acid—psoriasis	0.000235	0.00135	CcSEcCtD
Loperamide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000233	0.00134	CcSEcCtD
Loperamide—Urticaria—Prednisolone—psoriasis	0.000231	0.00133	CcSEcCtD
Loperamide—Fatigue—Triamcinolone—psoriasis	0.000231	0.00133	CcSEcCtD
Loperamide—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00023	0.00133	CcSEcCtD
Loperamide—Asthenia—Cyclosporine—psoriasis	0.00023	0.00132	CcSEcCtD
Loperamide—Loss of consciousness—Prednisone—psoriasis	0.000228	0.00131	CcSEcCtD
Loperamide—Pruritus—Cyclosporine—psoriasis	0.000226	0.00131	CcSEcCtD
Loperamide—Urticaria—Hydrocortisone—psoriasis	0.000226	0.0013	CcSEcCtD
Loperamide—Immune system disorder—Methotrexate—psoriasis	0.000225	0.0013	CcSEcCtD
Loperamide—Abdominal pain—Hydrocortisone—psoriasis	0.000225	0.0013	CcSEcCtD
Loperamide—Asthenia—Mycophenolate mofetil—psoriasis	0.000224	0.00129	CcSEcCtD
Loperamide—Pruritus—Mycophenolate mofetil—psoriasis	0.000221	0.00127	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000219	0.00126	CcSEcCtD
Loperamide—Diarrhoea—Cyclosporine—psoriasis	0.000219	0.00126	CcSEcCtD
Loperamide—Discomfort—Prednisone—psoriasis	0.000218	0.00126	CcSEcCtD
Loperamide—Hypersensitivity—Prednisolone—psoriasis	0.000215	0.00124	CcSEcCtD
Loperamide—Dyspepsia—Dexamethasone—psoriasis	0.000214	0.00123	CcSEcCtD
Loperamide—Dyspepsia—Betamethasone—psoriasis	0.000214	0.00123	CcSEcCtD
Loperamide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000214	0.00123	CcSEcCtD
Loperamide—Urticaria—Triamcinolone—psoriasis	0.000213	0.00123	CcSEcCtD
Loperamide—Dizziness—Cyclosporine—psoriasis	0.000212	0.00122	CcSEcCtD
Loperamide—Anaphylactic shock—Prednisone—psoriasis	0.000212	0.00122	CcSEcCtD
Loperamide—Gastrointestinal disorder—Betamethasone—psoriasis	0.00021	0.00121	CcSEcCtD
Loperamide—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00021	0.00121	CcSEcCtD
Loperamide—Hypersensitivity—Hydrocortisone—psoriasis	0.00021	0.00121	CcSEcCtD
Loperamide—Fatigue—Betamethasone—psoriasis	0.00021	0.00121	CcSEcCtD
Loperamide—Fatigue—Dexamethasone—psoriasis	0.00021	0.00121	CcSEcCtD
Loperamide—Nervous system disorder—Prednisone—psoriasis	0.000208	0.0012	CcSEcCtD
Loperamide—Dizziness—Mycophenolate mofetil—psoriasis	0.000206	0.00119	CcSEcCtD
Loperamide—Skin disorder—Prednisone—psoriasis	0.000206	0.00119	CcSEcCtD
Loperamide—Asthenia—Hydrocortisone—psoriasis	0.000204	0.00118	CcSEcCtD
Loperamide—Vomiting—Cyclosporine—psoriasis	0.000203	0.00117	CcSEcCtD
Loperamide—Rash—Cyclosporine—psoriasis	0.000202	0.00116	CcSEcCtD
Loperamide—Dermatitis—Cyclosporine—psoriasis	0.000202	0.00116	CcSEcCtD
Loperamide—Pruritus—Hydrocortisone—psoriasis	0.000201	0.00116	CcSEcCtD
Loperamide—Headache—Cyclosporine—psoriasis	0.0002	0.00116	CcSEcCtD
Loperamide—Gastrointestinal pain—Dexamethasone—psoriasis	0.000199	0.00115	CcSEcCtD
Loperamide—Gastrointestinal pain—Betamethasone—psoriasis	0.000199	0.00115	CcSEcCtD
Loperamide—Vomiting—Mycophenolate mofetil—psoriasis	0.000199	0.00114	CcSEcCtD
Loperamide—Hypersensitivity—Triamcinolone—psoriasis	0.000197	0.00114	CcSEcCtD
Loperamide—Rash—Mycophenolate mofetil—psoriasis	0.000197	0.00113	CcSEcCtD
Loperamide—Dermatitis—Mycophenolate mofetil—psoriasis	0.000197	0.00113	CcSEcCtD
Loperamide—Headache—Mycophenolate mofetil—psoriasis	0.000196	0.00113	CcSEcCtD
Loperamide—Diarrhoea—Hydrocortisone—psoriasis	0.000195	0.00112	CcSEcCtD
Loperamide—Urticaria—Betamethasone—psoriasis	0.000193	0.00111	CcSEcCtD
Loperamide—Urticaria—Dexamethasone—psoriasis	0.000193	0.00111	CcSEcCtD
Loperamide—Dizziness—Prednisolone—psoriasis	0.000193	0.00111	CcSEcCtD
Loperamide—Asthenia—Triamcinolone—psoriasis	0.000192	0.00111	CcSEcCtD
Loperamide—Abdominal pain—Dexamethasone—psoriasis	0.000192	0.00111	CcSEcCtD
Loperamide—Abdominal pain—Betamethasone—psoriasis	0.000192	0.00111	CcSEcCtD
Loperamide—Nausea—Cyclosporine—psoriasis	0.00019	0.0011	CcSEcCtD
Loperamide—Pruritus—Triamcinolone—psoriasis	0.000189	0.00109	CcSEcCtD
Loperamide—Dizziness—Hydrocortisone—psoriasis	0.000188	0.00108	CcSEcCtD
Loperamide—Dyspepsia—Prednisone—psoriasis	0.000186	0.00107	CcSEcCtD
Loperamide—Nausea—Mycophenolate mofetil—psoriasis	0.000185	0.00107	CcSEcCtD
Loperamide—Rash—Prednisolone—psoriasis	0.000184	0.00106	CcSEcCtD
Loperamide—Dermatitis—Prednisolone—psoriasis	0.000183	0.00106	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000183	0.00106	CcSEcCtD
Loperamide—Fatigue—Prednisone—psoriasis	0.000182	0.00105	CcSEcCtD
Loperamide—Headache—Prednisolone—psoriasis	0.000182	0.00105	CcSEcCtD
Loperamide—Discomfort—Methotrexate—psoriasis	0.000182	0.00105	CcSEcCtD
Loperamide—Constipation—Prednisone—psoriasis	0.000181	0.00104	CcSEcCtD
Loperamide—Vomiting—Hydrocortisone—psoriasis	0.000181	0.00104	CcSEcCtD
Loperamide—Rash—Hydrocortisone—psoriasis	0.000179	0.00103	CcSEcCtD
Loperamide—Dermatitis—Hydrocortisone—psoriasis	0.000179	0.00103	CcSEcCtD
Loperamide—Headache—Hydrocortisone—psoriasis	0.000178	0.00103	CcSEcCtD
Loperamide—Dizziness—Triamcinolone—psoriasis	0.000177	0.00102	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—psoriasis	0.000177	0.00102	CcSEcCtD
Loperamide—Asthenia—Betamethasone—psoriasis	0.000174	0.00101	CcSEcCtD
Loperamide—Asthenia—Dexamethasone—psoriasis	0.000174	0.00101	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—psoriasis	0.000173	0.001	CcSEcCtD
Loperamide—Gastrointestinal pain—Prednisone—psoriasis	0.000173	0.000998	CcSEcCtD
Loperamide—Nausea—Prednisolone—psoriasis	0.000173	0.000997	CcSEcCtD
Loperamide—Pruritus—Betamethasone—psoriasis	0.000172	0.000991	CcSEcCtD
Loperamide—Pruritus—Dexamethasone—psoriasis	0.000172	0.000991	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—psoriasis	0.000172	0.00099	CcSEcCtD
Loperamide—Vomiting—Triamcinolone—psoriasis	0.00017	0.000982	CcSEcCtD
Loperamide—Nausea—Hydrocortisone—psoriasis	0.000169	0.000974	CcSEcCtD
Loperamide—Rash—Triamcinolone—psoriasis	0.000169	0.000974	CcSEcCtD
Loperamide—Dermatitis—Triamcinolone—psoriasis	0.000169	0.000973	CcSEcCtD
Loperamide—Urticaria—Prednisone—psoriasis	0.000168	0.000969	CcSEcCtD
Loperamide—Headache—Triamcinolone—psoriasis	0.000168	0.000967	CcSEcCtD
Loperamide—Abdominal pain—Prednisone—psoriasis	0.000167	0.000964	CcSEcCtD
Loperamide—Diarrhoea—Dexamethasone—psoriasis	0.000166	0.000959	CcSEcCtD
Loperamide—Diarrhoea—Betamethasone—psoriasis	0.000166	0.000959	CcSEcCtD
Loperamide—Dizziness—Dexamethasone—psoriasis	0.000161	0.000926	CcSEcCtD
Loperamide—Dizziness—Betamethasone—psoriasis	0.000161	0.000926	CcSEcCtD
Loperamide—Nausea—Triamcinolone—psoriasis	0.000159	0.000917	CcSEcCtD
Loperamide—Somnolence—Methotrexate—psoriasis	0.000157	0.000906	CcSEcCtD
Loperamide—Hypersensitivity—Prednisone—psoriasis	0.000156	0.000899	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—psoriasis	0.000156	0.000898	CcSEcCtD
Loperamide—Vomiting—Dexamethasone—psoriasis	0.000155	0.000891	CcSEcCtD
Loperamide—Vomiting—Betamethasone—psoriasis	0.000155	0.000891	CcSEcCtD
Loperamide—Rash—Betamethasone—psoriasis	0.000153	0.000883	CcSEcCtD
Loperamide—Rash—Dexamethasone—psoriasis	0.000153	0.000883	CcSEcCtD
Loperamide—Dermatitis—Dexamethasone—psoriasis	0.000153	0.000883	CcSEcCtD
Loperamide—Dermatitis—Betamethasone—psoriasis	0.000153	0.000883	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—psoriasis	0.000153	0.00088	CcSEcCtD
Loperamide—Fatigue—Methotrexate—psoriasis	0.000152	0.000879	CcSEcCtD
Loperamide—Headache—Dexamethasone—psoriasis	0.000152	0.000878	CcSEcCtD
Loperamide—Headache—Betamethasone—psoriasis	0.000152	0.000878	CcSEcCtD
Loperamide—Asthenia—Prednisone—psoriasis	0.000152	0.000875	CcSEcCtD
Loperamide—Pruritus—Prednisone—psoriasis	0.00015	0.000863	CcSEcCtD
Loperamide—Diarrhoea—Prednisone—psoriasis	0.000145	0.000835	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—psoriasis	0.000145	0.000834	CcSEcCtD
Loperamide—Nausea—Dexamethasone—psoriasis	0.000144	0.000832	CcSEcCtD
Loperamide—Nausea—Betamethasone—psoriasis	0.000144	0.000832	CcSEcCtD
Loperamide—Urticaria—Methotrexate—psoriasis	0.000141	0.00081	CcSEcCtD
Loperamide—Dizziness—Prednisone—psoriasis	0.00014	0.000807	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—psoriasis	0.00014	0.000806	CcSEcCtD
Loperamide—Vomiting—Prednisone—psoriasis	0.000135	0.000776	CcSEcCtD
Loperamide—Rash—Prednisone—psoriasis	0.000133	0.000769	CcSEcCtD
Loperamide—Dermatitis—Prednisone—psoriasis	0.000133	0.000769	CcSEcCtD
Loperamide—Headache—Prednisone—psoriasis	0.000133	0.000764	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—psoriasis	0.00013	0.000751	CcSEcCtD
Loperamide—Asthenia—Methotrexate—psoriasis	0.000127	0.000732	CcSEcCtD
Loperamide—Nausea—Prednisone—psoriasis	0.000126	0.000725	CcSEcCtD
Loperamide—Pruritus—Methotrexate—psoriasis	0.000125	0.000721	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—psoriasis	0.000121	0.000698	CcSEcCtD
Loperamide—Dizziness—Methotrexate—psoriasis	0.000117	0.000674	CcSEcCtD
Loperamide—Vomiting—Methotrexate—psoriasis	0.000112	0.000648	CcSEcCtD
Loperamide—Rash—Methotrexate—psoriasis	0.000112	0.000643	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—psoriasis	0.000111	0.000642	CcSEcCtD
Loperamide—Headache—Methotrexate—psoriasis	0.000111	0.000639	CcSEcCtD
Loperamide—Nausea—Methotrexate—psoriasis	0.000105	0.000606	CcSEcCtD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.74e-05	0.00021	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—IL6—psoriasis	2.74e-05	0.00021	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—IL6—psoriasis	2.74e-05	0.00021	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL20—psoriasis	2.74e-05	0.00021	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—CXCL8—psoriasis	2.73e-05	0.000209	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—IL6—psoriasis	2.72e-05	0.000209	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—IL6—psoriasis	2.72e-05	0.000209	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-E—psoriasis	2.7e-05	0.000207	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-E—psoriasis	2.7e-05	0.000207	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—IL6—psoriasis	2.7e-05	0.000207	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—IL6—psoriasis	2.7e-05	0.000207	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CARM1—psoriasis	2.69e-05	0.000206	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CARM1—psoriasis	2.69e-05	0.000206	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-DRB1—psoriasis	2.68e-05	0.000206	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-DRB1—psoriasis	2.68e-05	0.000206	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—IL6—psoriasis	2.68e-05	0.000206	CbGpPWpGaD
Loperamide—CALM1—Signaling by PDGF—IL6—psoriasis	2.68e-05	0.000206	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—STAT3—psoriasis	2.68e-05	0.000205	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—STAT3—psoriasis	2.68e-05	0.000205	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—ICAM1—psoriasis	2.66e-05	0.000204	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—NFKBIA—psoriasis	2.66e-05	0.000204	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—NFKBIA—psoriasis	2.66e-05	0.000204	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP2S1—psoriasis	2.66e-05	0.000204	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL20—psoriasis	2.65e-05	0.000203	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL20—psoriasis	2.65e-05	0.000203	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—NFKBIA—psoriasis	2.64e-05	0.000203	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	2.63e-05	0.000202	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.6e-05	0.000199	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—ICAM1—psoriasis	2.58e-05	0.000198	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—ICAM1—psoriasis	2.58e-05	0.000198	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—NFKBIA—psoriasis	2.56e-05	0.000196	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—NFKBIA—psoriasis	2.56e-05	0.000196	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.51e-05	0.000193	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.51e-05	0.000192	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—TP53—psoriasis	2.49e-05	0.000191	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SOCS1—psoriasis	2.43e-05	0.000187	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.43e-05	0.000186	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.43e-05	0.000186	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—APOE—psoriasis	2.42e-05	0.000186	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—LEP—psoriasis	2.42e-05	0.000186	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CARM1—psoriasis	2.42e-05	0.000186	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—CXCL8—psoriasis	2.39e-05	0.000183	CbGpPWpGaD
Loperamide—CALM3—Immune System—SOCS1—psoriasis	2.33e-05	0.000179	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—TYK2—psoriasis	2.32e-05	0.000178	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—IL6—psoriasis	2.28e-05	0.000175	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.26e-05	0.000174	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—NFKBIA—psoriasis	2.26e-05	0.000173	CbGpPWpGaD
Loperamide—CALM1—Immune System—SOCS1—psoriasis	2.25e-05	0.000173	CbGpPWpGaD
Loperamide—CALM2—Immune System—SOCS1—psoriasis	2.25e-05	0.000173	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—TYK2—psoriasis	2.25e-05	0.000173	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	2.23e-05	0.000171	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.21e-05	0.000169	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—TYK2—psoriasis	2.18e-05	0.000167	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—TYK2—psoriasis	2.18e-05	0.000167	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—APOE—psoriasis	2.13e-05	0.000163	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—LEP—psoriasis	2.13e-05	0.000163	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CARM1—psoriasis	2.11e-05	0.000162	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD8A—psoriasis	2.07e-05	0.000159	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—CD4—psoriasis	2.04e-05	0.000156	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—CXCL8—psoriasis	2.02e-05	0.000155	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD8A—psoriasis	2e-05	0.000153	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD8A—psoriasis	2e-05	0.000153	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-B—psoriasis	1.99e-05	0.000152	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CARM1—psoriasis	1.99e-05	0.000152	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NFKBIA—psoriasis	1.98e-05	0.000152	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—CD4—psoriasis	1.97e-05	0.000151	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—CD4—psoriasis	1.97e-05	0.000151	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD4—psoriasis	1.96e-05	0.00015	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—IL6—psoriasis	1.93e-05	0.000148	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-B—psoriasis	1.92e-05	0.000148	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-B—psoriasis	1.92e-05	0.000148	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD4—psoriasis	1.89e-05	0.000145	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD4—psoriasis	1.89e-05	0.000145	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—IL6—psoriasis	1.87e-05	0.000143	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—IL6—psoriasis	1.87e-05	0.000143	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TYK2—psoriasis	1.85e-05	0.000142	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-A—psoriasis	1.84e-05	0.000141	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—JUN—psoriasis	1.82e-05	0.00014	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—LEP—psoriasis	1.8e-05	0.000138	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—APOE—psoriasis	1.8e-05	0.000138	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-A—psoriasis	1.78e-05	0.000137	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-A—psoriasis	1.78e-05	0.000137	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—VEGFA—psoriasis	1.77e-05	0.000136	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—JUN—psoriasis	1.76e-05	0.000135	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—JUN—psoriasis	1.76e-05	0.000135	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CAT—psoriasis	1.76e-05	0.000135	CbGpPWpGaD
Loperamide—CALM3—Immune System—CRP—psoriasis	1.76e-05	0.000135	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—NFKB1—psoriasis	1.76e-05	0.000135	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—VEGFA—psoriasis	1.71e-05	0.000131	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—VEGFA—psoriasis	1.71e-05	0.000131	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CAT—psoriasis	1.71e-05	0.000131	CbGpPWpGaD
Loperamide—CALM3—Disease—HLA-A—psoriasis	1.7e-05	0.00013	CbGpPWpGaD
Loperamide—CALM1—Immune System—CRP—psoriasis	1.7e-05	0.00013	CbGpPWpGaD
Loperamide—CALM2—Immune System—CRP—psoriasis	1.7e-05	0.00013	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—NFKB1—psoriasis	1.7e-05	0.00013	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—NFKB1—psoriasis	1.7e-05	0.00013	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—NFKB1—psoriasis	1.69e-05	0.000129	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-DRB1—psoriasis	1.68e-05	0.000129	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NFKBIA—psoriasis	1.67e-05	0.000128	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CAT—psoriasis	1.66e-05	0.000127	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CAT—psoriasis	1.66e-05	0.000127	CbGpPWpGaD
Loperamide—CALM2—Disease—HLA-A—psoriasis	1.65e-05	0.000126	CbGpPWpGaD
Loperamide—CALM1—Disease—HLA-A—psoriasis	1.65e-05	0.000126	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—NFKB1—psoriasis	1.63e-05	0.000125	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—NFKB1—psoriasis	1.63e-05	0.000125	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-DRB1—psoriasis	1.63e-05	0.000125	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-DRB1—psoriasis	1.63e-05	0.000125	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TYK2—psoriasis	1.62e-05	0.000124	CbGpPWpGaD
Loperamide—CALM3—Immune System—ICAM1—psoriasis	1.62e-05	0.000124	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CXCL8—psoriasis	1.61e-05	0.000124	CbGpPWpGaD
Loperamide—CALM3—Immune System—NFKBIA—psoriasis	1.6e-05	0.000123	CbGpPWpGaD
Loperamide—CALM3—Disease—APOE—psoriasis	1.59e-05	0.000122	CbGpPWpGaD
Loperamide—CALM1—Immune System—ICAM1—psoriasis	1.56e-05	0.00012	CbGpPWpGaD
Loperamide—CALM2—Immune System—ICAM1—psoriasis	1.56e-05	0.00012	CbGpPWpGaD
Loperamide—CALM2—Immune System—NFKBIA—psoriasis	1.55e-05	0.000119	CbGpPWpGaD
Loperamide—CALM1—Immune System—NFKBIA—psoriasis	1.55e-05	0.000119	CbGpPWpGaD
Loperamide—CALM2—Disease—APOE—psoriasis	1.54e-05	0.000118	CbGpPWpGaD
Loperamide—CALM1—Disease—APOE—psoriasis	1.54e-05	0.000118	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—IL6—psoriasis	1.53e-05	0.000117	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SOCS1—psoriasis	1.51e-05	0.000116	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—JUN—psoriasis	1.5e-05	0.000115	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CAT—psoriasis	1.49e-05	0.000114	CbGpPWpGaD
Loperamide—CALM3—Disease—NOS2—psoriasis	1.48e-05	0.000113	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SOCS1—psoriasis	1.46e-05	0.000112	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SOCS1—psoriasis	1.46e-05	0.000112	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—NFKB1—psoriasis	1.44e-05	0.000111	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—TYK2—psoriasis	1.44e-05	0.00011	CbGpPWpGaD
Loperamide—CALM1—Disease—NOS2—psoriasis	1.43e-05	0.00011	CbGpPWpGaD
Loperamide—CALM2—Disease—NOS2—psoriasis	1.43e-05	0.00011	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CXCL8—psoriasis	1.41e-05	0.000108	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—TYK2—psoriasis	1.39e-05	0.000107	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—TYK2—psoriasis	1.39e-05	0.000107	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TYK2—psoriasis	1.37e-05	0.000105	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—APOE—psoriasis	1.37e-05	0.000105	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—IL6—psoriasis	1.34e-05	0.000103	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—psoriasis	1.34e-05	0.000103	CbGpPWpGaD
Loperamide—CALM3—Metabolism—APOE—psoriasis	1.33e-05	0.000102	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—JUN—psoriasis	1.31e-05	0.000101	CbGpPWpGaD
Loperamide—CALM3—Immune System—TYK2—psoriasis	1.31e-05	0.000101	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—VEGFA—psoriasis	1.31e-05	0.0001	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CARM1—psoriasis	1.3e-05	9.96e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CAT—psoriasis	1.3e-05	9.95e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—STAT3—psoriasis	1.3e-05	9.93e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—psoriasis	1.29e-05	9.92e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—psoriasis	1.29e-05	9.92e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—APOE—psoriasis	1.29e-05	9.87e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—APOE—psoriasis	1.29e-05	9.87e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—TYK2—psoriasis	1.27e-05	9.74e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—TYK2—psoriasis	1.27e-05	9.74e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NFKB1—psoriasis	1.26e-05	9.69e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CXCL8—psoriasis	1.25e-05	9.59e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IFNG—psoriasis	1.23e-05	9.43e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CAT—psoriasis	1.22e-05	9.37e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—TYK2—psoriasis	1.21e-05	9.29e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CXCL8—psoriasis	1.21e-05	9.28e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CXCL8—psoriasis	1.21e-05	9.28e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CXCL8—psoriasis	1.19e-05	9.16e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PPARG—psoriasis	1.19e-05	9.13e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IFNG—psoriasis	1.19e-05	9.12e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IFNG—psoriasis	1.19e-05	9.12e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD4—psoriasis	1.19e-05	9.1e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—TYK2—psoriasis	1.17e-05	8.99e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—TYK2—psoriasis	1.17e-05	8.99e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PPARG—psoriasis	1.16e-05	8.88e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—APOE—psoriasis	1.16e-05	8.87e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD4—psoriasis	1.15e-05	8.81e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD4—psoriasis	1.15e-05	8.81e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—psoriasis	1.15e-05	8.8e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—STAT3—psoriasis	1.14e-05	8.71e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL6—psoriasis	1.14e-05	8.71e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PPARG—psoriasis	1.12e-05	8.59e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PPARG—psoriasis	1.12e-05	8.59e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—LEP—psoriasis	1.11e-05	8.53e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APOE—psoriasis	1.11e-05	8.53e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—JUN—psoriasis	1.11e-05	8.51e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IL6—psoriasis	1.1e-05	8.45e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CD4—psoriasis	1.1e-05	8.41e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—LEP—psoriasis	1.08e-05	8.25e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APOE—psoriasis	1.08e-05	8.25e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—LEP—psoriasis	1.08e-05	8.25e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APOE—psoriasis	1.08e-05	8.25e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NFKB1—psoriasis	1.07e-05	8.19e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IL6—psoriasis	1.07e-05	8.18e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IL6—psoriasis	1.07e-05	8.18e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—JUN—psoriasis	1.06e-05	8.15e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CD4—psoriasis	1.06e-05	8.13e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CD4—psoriasis	1.06e-05	8.13e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NFKBIA—psoriasis	1.04e-05	7.95e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—JUN—psoriasis	1.03e-05	7.88e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—JUN—psoriasis	1.03e-05	7.88e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NFKB1—psoriasis	1.02e-05	7.84e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—APOE—psoriasis	1.01e-05	7.73e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PPARG—psoriasis	1.01e-05	7.73e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NFKBIA—psoriasis	1e-05	7.69e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NFKBIA—psoriasis	1e-05	7.69e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NFKB1—psoriasis	9.89e-06	7.59e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NFKB1—psoriasis	9.89e-06	7.59e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—psoriasis	9.89e-06	7.58e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—psoriasis	9.7e-06	7.44e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—STAT3—psoriasis	9.6e-06	7.36e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—APOE—psoriasis	9.5e-06	7.28e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—STAT3—psoriasis	9.19e-06	7.05e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—psoriasis	9.05e-06	6.94e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—STAT3—psoriasis	8.89e-06	6.82e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—STAT3—psoriasis	8.89e-06	6.82e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARG—psoriasis	8.78e-06	6.73e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—psoriasis	8.67e-06	6.65e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TYK2—psoriasis	8.49e-06	6.51e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—STAT3—psoriasis	8.49e-06	6.51e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARG—psoriasis	8.27e-06	6.34e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TYK2—psoriasis	8.21e-06	6.3e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TYK2—psoriasis	8.21e-06	6.3e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—STAT3—psoriasis	8.21e-06	6.3e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—STAT3—psoriasis	8.21e-06	6.3e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CAT—psoriasis	7.99e-06	6.13e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—psoriasis	7.93e-06	6.08e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL8—psoriasis	7.39e-06	5.67e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—psoriasis	7.33e-06	5.62e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL8—psoriasis	7.15e-06	5.48e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL8—psoriasis	7.15e-06	5.48e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—psoriasis	7.03e-06	5.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—JUN—psoriasis	6.87e-06	5.27e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—psoriasis	6.8e-06	5.21e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—psoriasis	6.8e-06	5.21e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—psoriasis	6.71e-06	5.14e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—JUN—psoriasis	6.65e-06	5.1e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—JUN—psoriasis	6.65e-06	5.1e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NFKB1—psoriasis	6.61e-06	5.07e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—psoriasis	6.42e-06	4.92e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NFKB1—psoriasis	6.4e-06	4.91e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NFKB1—psoriasis	6.4e-06	4.91e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—psoriasis	6.21e-06	4.76e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—psoriasis	6.21e-06	4.76e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOE—psoriasis	6.21e-06	4.76e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—psoriasis	6e-06	4.6e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—STAT3—psoriasis	5.94e-06	4.56e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—psoriasis	5.93e-06	4.55e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—psoriasis	5.81e-06	4.45e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—psoriasis	5.81e-06	4.45e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—STAT3—psoriasis	5.75e-06	4.41e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—STAT3—psoriasis	5.75e-06	4.41e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—psoriasis	5.73e-06	4.4e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—psoriasis	5.73e-06	4.4e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARG—psoriasis	5.41e-06	4.15e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—psoriasis	4.53e-06	3.48e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—psoriasis	4.39e-06	3.36e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—psoriasis	4.39e-06	3.36e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—psoriasis	4.15e-06	3.18e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—psoriasis	4.02e-06	3.08e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—psoriasis	4.02e-06	3.08e-05	CbGpPWpGaD
